TY - JOUR
T1 - Engineered exosomes for studies in tumor immunology
AU - Alptekin, Ahmet
AU - Parvin, Mahrima
AU - Chowdhury, Hasanul I.
AU - Rashid, Mohammad H.
AU - Arbab, Ali S.
N1 - Funding Information:
The study was funded by American Heart Associate (AHA) grant 19TPA34850076 and part of the Georgia Cancer Center start‐up fund and NIH grant R01NS110378 to ASA.
Funding Information:
The study was funded by American Heart Associate (AHA) grant 19TPA34850076 and part of the Georgia Cancer Center start-up fund and NIH grant R01NS110378 to ASA.
Publisher Copyright:
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2022/11
Y1 - 2022/11
N2 - Exosomes are a type of extracellular vesicle (EV) with diameters of 30–150 nm secreted by most of the cells into the extracellular spaces and can alter the microenvironment through cell-to-cell interactions by fusion with the plasma membrane and subsequent endocytosis and release of the cargo. Because of their biocompatibility, low toxicity and immunogenicity, permeability (even through the blood–brain barrier (BBB)), stability in biological fluids, and ability to accumulate in the lesions with higher specificity, investigators have started making designer's exosomes or engineered exosomes to carry biologically active protein on the surface or inside the exosomes as well as using exosomes to carry drugs, micro RNA, and other products to the site of interest. In this review, we have discussed biogenesis, markers, and contents of various exosomes including exosomes of immune cells. We have also discussed the current methods of making engineered and designer's exosomes as well as the use of engineered exosomes targeting different immune cells in the tumors, stroke, as well as at peripheral blood. Genetic engineering and customizing exosomes create an unlimited opportunity to use in diagnosis and treatment. Very little use has been discovered, and we are far away to reach its limits.
AB - Exosomes are a type of extracellular vesicle (EV) with diameters of 30–150 nm secreted by most of the cells into the extracellular spaces and can alter the microenvironment through cell-to-cell interactions by fusion with the plasma membrane and subsequent endocytosis and release of the cargo. Because of their biocompatibility, low toxicity and immunogenicity, permeability (even through the blood–brain barrier (BBB)), stability in biological fluids, and ability to accumulate in the lesions with higher specificity, investigators have started making designer's exosomes or engineered exosomes to carry biologically active protein on the surface or inside the exosomes as well as using exosomes to carry drugs, micro RNA, and other products to the site of interest. In this review, we have discussed biogenesis, markers, and contents of various exosomes including exosomes of immune cells. We have also discussed the current methods of making engineered and designer's exosomes as well as the use of engineered exosomes targeting different immune cells in the tumors, stroke, as well as at peripheral blood. Genetic engineering and customizing exosomes create an unlimited opportunity to use in diagnosis and treatment. Very little use has been discovered, and we are far away to reach its limits.
KW - designer's exosomes
KW - engineered exosomes
KW - manipulation of biogenesis, exosomes, and immune cells
KW - separation of exosomes
KW - therapeutic exosomes
UR - http://www.scopus.com/inward/record.url?scp=85133592283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133592283&partnerID=8YFLogxK
U2 - 10.1111/imr.13107
DO - 10.1111/imr.13107
M3 - Review article
C2 - 35808839
AN - SCOPUS:85133592283
SN - 0105-2896
VL - 312
SP - 76
EP - 102
JO - Immunological Reviews
JF - Immunological Reviews
IS - 1
ER -